ANGPTL4 and focal segmental glomerulosclerosis: in 2017, which included 60 MCD and 52 FSGS patients, did not confirm these findings and found lower serum Angptl4 levels in patients with MCD, FSGS, and membranous nephropathy during relapse compared to controls.